Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia

19 Sept 2023

Abstract excerpt

Despite the potential of CAR-T therapies for hematological malignancies, their efficacy in patients with relapse and refractory Acute Myeloid Leukemia has been limited. The aim of our study has been to develop and manufacture a CAR-T cell product that addresses some of the current limitations. We initially compared the phenotype of T cells from AML patients and healthy young and elderly controls. This analysis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to CRISPR and Genetic Engineering
Share to Viral Infectious Diseases and Gene Expression in Insects

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37795087
DOI: 10.3389/fimmu.2023.1270843

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemiaPMID 37795087Read ↗

The Black Hole: CAR T Cell Therapy in AMLSemantic proximity Read ↗

The Black Hole: CAR T cell Therapy in AMLSemantic proximity Read ↗

Engineering strategies to safely drive CAR T-cells into the futureSemantic proximity Read ↗

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editingSemantic proximity Read ↗

Generating universal anti-CD19 CAR T cells with a defined memory phenotype by CRISPR/Cas9 editing and safety evaluation of the transcriptome.Semantic proximity Read ↗

Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screeningSemantic proximity Read ↗

A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapiesSemantic proximity Read ↗

Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphomaSemantic proximity Read ↗

CAR T-cell Therapy: A New Era in Cancer ImmunotherapySemantic proximity Read ↗

Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell MalignanciesSemantic proximity Read ↗

Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapySemantic proximity Read ↗

Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon SystemSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.